Centessa Pharmaceuticals (CNTA)

Executive Summary

Centessa Pharmaceuticals has pivoted its focus to its Orexin Receptor 2 Agonist Program, targeting sleep-wake and neurological disorders. The lead asset, ORX750, is in Phase 2 trials for narcolepsy and idiopathic hypersomnia, with two recruiting studies underway. Additionally, ORX142 is in Phase 1 for excessive daytime sleepiness, and ORX489 is in Phase 1 as a potential next-generation candidate. The company has terminated several prior programs in hemophilia and oncology, concentrating resources on the orexin pipeline. With initial data expected within the next 6-12 months, Centessa represents a high-risk, high-reward opportunity in the orexin agonist space, addressing significant unmet needs in sleep disorders. The company's platform has garnered attention, but clinical proof-of-concept remains to be established.

Upcoming Catalysts (preview)

• Q4 2026ORX750 Phase 2 top-line data in narcolepsy35% success
• Q3 2026ORX142 Phase 1 safety and efficacy data50% success
• Q2 2027Initial ORX489 Phase 1 healthy volunteer results60% success